Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...

New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...

Healio Pulmonology has compiled the top news on COPD posted in 2025.Readers were most interested in how pulmonary ...

The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a ...